Botulinum Toxin-A May Help Patients With Diabetic Neuropathy

Share this content:
There was no statistically significant effect on adverse events in terms of infection at injection site.
There was no statistically significant effect on adverse events in terms of infection at injection site.

HealthDay News -- Botulinum toxin-A (BTX-A) appears to be beneficial for painful diabetic neuropathy (PDN), according to a meta-analysis published online in Pain Medicine.

Shaheen E. Lakhan, MD, PhD, from the Global Neuroscience Initiative Foundation in Los Angeles, and colleagues conducted a meta-analysis of two studies using BTX-A in the treatment of neuropathic pain. The difference in visual analog scale (VAS) from pre-intervention to one month post-intervention was measured as the primary outcome.

The researchers found that following treatment with BTX-A there was an improvement of 1.96 VAS points (P < 0.001), which corresponded to a clinically significant improvement of "minimum change in pain." There was no statistically significant effect on adverse events in terms of infection at injection site (P = 0.49).

"Tests for significance, low overall risk of bias, and almost no statistical heterogeneity suggests that there is a correlation between BTX-A and improvement of pain scores in PDN," the authors write.

Reference

  1. Lakhan SE et al. Pain Med. 2015;doi:10.1111/pme.12728.
You must be a registered member of Clinical Pain Advisor to post a comment.